Ellagic acid supplementation in women with the poly cystic ovarian syndrome

Assessment of the ellagic acid supplementation effect on insulin resistance, oxidative stress and sex hormones levels in women with the Polycystic ovary syndrome.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141025019669N12

Enrollment

Registered

2019-07-07

Start date

2019-05-31

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Ellagic acid, a capsule 200 mg per daily for two months, Manufacturer: Supplement Spot. Intervention 2: Control group: A daily placebo capsule containing wheat flou

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Women with the poly cystic ovarian syndrome

Exclusion criteria

Exclusion criteria: Use of contraceptives, glucocorticoids and lipid lowering drugs over the past three months

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sex hormones. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Anti-Müllerian hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sleep quality. Timepoint: Before intervention and after intervention. Method of measurement: Petersburg’s sleep quality questionnaire.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sex hormones. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Anti-Müllerian hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Sleep quality. Timepoint: Before intervention and after intervention. Method of measurement: Petersburg’s sleep quality questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Khadem Haghighian

Qazvin University of Medical Sciences

khademnut@yahoo.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 21, 2026